Literature DB >> 12925003

Induced down-regulation of neuropeptide Y-Y1 receptors delays initiation of kindling.

Ramla Benmaamar1, Bich-Thuy Pham-Lê, Christian Marescaux, Thierry Pedrazzini, Antoine Depaulis.   

Abstract

Neuropeptide Y appears to modulate epileptic seizures differentially according to the receptor subtypes involved. In the hippocampus, neuropeptide Y expression and release are enhanced in different models of epileptogenesis. On the contrary, the expression of Y1 receptors is decreased and it has been shown that activation of these receptors has pro-convulsant effects. The aim of our study was to investigate the role of Y1 receptors during hippocampal kindling epileptogenesis using (i) knock-out mice lacking Y1 receptors and (ii) intrahippocampal infusion of Y1 antisense oligodeoxynucleotide in rats. Y1 knock-out mice showed similar susceptibility to seizure induction and presented no difference in kindling development as compared with their control littermates. Conversely, local hippocampal down-regulation of Y1 receptors during the first week of hippocampal kindling, induced by a local infusion of a Y1 antisense oligodeoxynucleotide, significantly increased seizure threshold intensity and decreased afterdischarge duration. A reverse effect was observed during the week following the infusion period, which was confirmed by a significant decrease in the number of hippocampal stimulations necessary to evoke generalized seizures. At the end of this second week, an up-regulation of Y1 receptors was observed in kindled rats infused with the antisense as compared with the mismatch-treated controls. Our results in the rat suggest that the down-regulation of Y1 receptors in the hippocampus participates in the control of the initiation of epileptogenesis. The lack of an effect of the deficiency of Y1 receptors in the control of kindling development in Y1 knock-out mice could be due to compensatory mechanisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12925003     DOI: 10.1046/j.1460-9568.2003.02810.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  7 in total

1.  Neuropeptide Y and Y1 receptors in kindling epileptogenesis.

Authors:  Annamaria Vezzani
Journal:  Epilepsy Curr       Date:  2004 May-Jun       Impact factor: 7.500

2.  NPY Receptors Blockade Prevents Anticonvulsant Action of Ghrelin in the Hippocampus of Rat.

Authors:  Mina Ghahramanian Golzar; Shirin Babri; Zohre Ataie; Hadi Ebrahimi; Fariba Mirzaie; Gisou Mohaddes
Journal:  Adv Pharm Bull       Date:  2013-08-20

Review 3.  Gene and Cell Therapy for Epilepsy: A Mini Review.

Authors:  Alisa A Shaimardanova; Daria S Chulpanova; Aysilu I Mullagulova; Zaid Afawi; Rimma G Gamirova; Valeriya V Solovyeva; Albert A Rizvanov
Journal:  Front Mol Neurosci       Date:  2022-05-11       Impact factor: 6.261

4.  Gene Therapy Vector Encoding Neuropeptide Y and Its Receptor Y2 for Future Treatment of Epilepsy: Preclinical Data in Rats.

Authors:  Julia Alicja Szczygieł; Kira Iben Danielsen; Esbjörn Melin; Søren Hofman Rosenkranz; Stanislava Pankratova; Annika Ericsson; Karin Agerman; Merab Kokaia; David Paul Drucker Woldbye
Journal:  Front Mol Neurosci       Date:  2020-12-04       Impact factor: 5.639

Review 5.  NPY and Gene Therapy for Epilepsy: How, When,... and Y.

Authors:  Stefano Cattaneo; Gianluca Verlengia; Pietro Marino; Michele Simonato; Barbara Bettegazzi
Journal:  Front Mol Neurosci       Date:  2021-01-22       Impact factor: 5.639

6.  Disease Modification by Combinatorial Single Vector Gene Therapy: A Preclinical Translational Study in Epilepsy.

Authors:  Esbjörn Melin; Avtandil Nanobashvili; Una Avdic; Casper R Gøtzsche; My Andersson; David P D Woldbye; Merab Kokaia
Journal:  Mol Ther Methods Clin Dev       Date:  2019-09-18       Impact factor: 6.698

Review 7.  Pathological Targets for Treating Temporal Lobe Epilepsy: Discoveries From Microscale to Macroscale.

Authors:  Jing You; Haiyan Huang; Clement T Y Chan; Lin Li
Journal:  Front Neurol       Date:  2022-01-07       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.